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Available online 25 November 2015Background:HIV-infectedpatientswith pulmonary TB (pTB) canhaveworsening of respiratory symptoms as part
of TB-immune reconstitution inﬂammatory syndrome (TB-IRIS) following antiretroviral therapy (ART) initiation.
Thus, reconstitution of immune function on ART could drive incident lung damage in HIV/TB.
Methods:Wehypothesized that increases inmatrix metalloproteinases (MMPs), which can degrade lungmatrix,
on ART are associated with TB-IRIS among a cohort of advanced, ART naïve, HIV-infected adults with pTB. Fur-
thermore, we related early changes in immune measures and MMPs on ART to lung function in an exploratory
subset of patients post-TB cure. This study was nested within a prospective cohort study. Rank sum and
chi-square tests, Spearman's correlation coefﬁcient, and logistic regression were used for analyses.
Results: Increases in MMP-8 following ART initiation were independently associated with TB-IRIS (p = 0.04;
adjusted odds ratio 1.5 [95% conﬁdence interval: 1.0–2.1]; n = 32). Increases in CD4 counts and MMP-8 on
ART were also associated with reduced forced expiratory volume in one-second post-TB treatment completion
(r =−0.7, p = 0.006 and r =−0.6, p = 0.02, respectively; n = 14).
Conclusions: ART-induced MMP increases are associated with TB-IRIS andmay affect lung function post-TB cure.
End-organ damage due to TB-IRIS and mechanisms whereby immune restoration impairs lung function in pTB
deserve further investigation.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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ART1. Introduction
Formany patientswith TB, themorbidity of the disease extends long
beyond TB treatment completion (Pasipanodya et al. 2010). Indeed,
approximately half of patients surviving pulmonary TB (pTB), the
most common form of the disease, suffer substantial long-term pulmo-
nary impairment despite microbiologic cure (Pasipanodya et al. 2010;
Hnizdo et al. 2000; Ralph et al. 2013). Furthermore, pTB, including
cured disease, is a major cause of chronic lung disease worldwide
(van Zyl Smit et al. 2010).
Nearly 15% of all TB cases and 25% of global TB deaths are
HIV-associated (WHO 2014). The underlying mechanisms leadingedicine at the University of
, Philadelphia, PA 19104, USA.
imohan).
. This is an open access article underto long-term pulmonary morbidity after TB treatment completion, es-
pecially among HIV-infected patients, are unclear (Pasipanodya et al.
2010; Hnizdo et al. 2000; Ralph et al. 2013). Clinically, impaired lung
function after TB treatment completion is associatedwith greater radio-
graphic lung involvement at initial presentation (Plit et al. 1998). Great-
er initial radiographic lung involvement is also associated with higher
CD4 counts in individuals with HIV/TB (Kwan and Ernst 2011; Post
et al. 1995). These ﬁndings are consistent with a central role of
cellular immune responses in cavity formation and structural lung dam-
age in TB (Flynn et al. 1993; Schluger et al. 2002). Mechanistically, ma-
trixmetalloproteinases (MMPs), which can degrade lung collagen, have
also been implicated in TB-associated lung tissue destruction (Greenlee
et al. 2007; Ong et al. 2014; Elkington et al. 2011). However, lowerMMP
concentrations and reduced TB-associated lung damage assessed radio-
graphically have been associated with HIV infection (Walker et al.
2012). Taken together, these data suggest that patients with HIV maythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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this association are conﬂicting (Hnizdo et al. 2000; Ralph et al. 2013).
Antiretroviral therapy (ART) is a critical component of HIV/TB care,
conferring a survival advantage to those who initiate ART during
treatment of TB (Abdool Karim et al. 2011; Abdool Karim et al. 2010).
While ART use in a study of HIV-infected patients was independently
associated with airway obstruction (George et al. 2009), a limitation of
studies relating HIV to lung damage in TB is that the effects of cellular
immune restoration during TB treatment have not been assessed in de-
tail. Rapid cellular immune restoration in the presence of a high TB an-
tigen burden could plausibly drive incident cavity formation and
worsening lung damage. Consistent with this hypothesis, case reports
have described patients with advanced HIV/pTB and minimal initial
radiographic lung involvement who develop massive pulmonary
inﬁltrates, lung cavitation, and bronchiolitis obliterans soon after ART
initiation (Meintjes et al. 2008; Lawn et al. 2009). Incident lung damage
during immune restoration in HIV/TB may also complicate TB-immune
reconstitution inﬂammatory syndrome (TB-IRIS), but this hypothesis
has been relatively unexplored. In one study, HIV/TB co-infected
adults who experienced TB-IRIS on ART were found to have higher
absolute concentrations of MMPs at the time of the IRIS event com-
pared to controls, but lung function was not assessed (Tadokera
et al. 2014).
In this study, we investigated changes in MMP concentrations on
ART and the association between these changes and paradoxical TB-
IRIS in awell-characterized cohort of HIV-infected adultswith advanced
HIV/TB (Ravimohan et al. 2013; Ravimohan et al. 2015a). Furthermore,
in a subset of patients, we explored the relationship between the mag-
nitude of early immune restoration and MMP concentrations on ART
and pulmonary function after TB treatment completion. We speciﬁcally
selected MMP-1, -2, -3, -8, and -9 for analysis, as they have previously
been found to be associated with lung tissue damage in TB (Elkington
et al. 2011; Walker et al. 2012; Elkington et al. 2005; Elkington and
Friedland 2006; Ong et al. 2015).
2. Materials and Methods
2.1. Ethics
The institutional review boards of the University of Pennsylvania,
Botswana Ministry of Health, and the Princess Marina Hospital
approved this study. All patients provided written informed consent
to participate in this study.
2.2. Study Design
We enrolled ART naïve, HIV-infected adults with pulmonary TB in
a prospective cohort study to investigate the relationship between
early immune recovery on ART and treatment outcomes, as described
(Ravimohan et al. 2013; Ravimohan et al. 2015a). This cohort has
previously demonstrated that early changes (measured during the
ﬁrst 4 weeks of ART) in CD4 counts and other immunologic parameters
are differentially associated with death and paradoxical TB-IRIS
(Ravimohan et al. 2015a). TB-IRIS in this cohort was symptomatically
characterized primarily by worsening respiratory status (Ravimohan
et al. 2015a). In this secondary analysis we therefore hypothesized
that 1) concentrations of MMPs would increase after ART initiation
and 2) early changes in MMPs would be associated with paradoxical
TB-IRIS. Finally, in a subset of patients, we explored the hypothesis
that rapid increases in CD4 counts, Mycobacterium tuberculosis
(MTB)-speciﬁc cellular immune function, and MMP concentrations
early after ART initiation during TB treatment, as well as TB-IRIS within
6 months after ART initiation, would be associated with impaired lung
function. Lung function was assessed months after TB treatment com-
pletion to focus on stable residual effects after TB cure (Hnizdo et al.
2000).2.3. Study Participants
Patients were enrolled into the parent study between November
2009 and July 2013 from outpatient clinics and a public tertiary care
hospital in Gaborone, Botswana, as described (Ravimohan et al. 2013;
Ravimohan et al. 2015a). Subjects had to have a pre-ART CD4 count
≤125 cells/μl and plan to initiate ART within 2 months of starting
standard TB treatment for their newly diagnosed pulmonary TB
(Ravimohan et al. 2013; Ravimohan et al. 2015a). Given our focus on
possible effects of immune recovery on lung related parameters in
those who survive TB, to be included in the primary analysis relating
MMP concentrations and TB-IRIS, patients required baseline and week
4 post-ART initiation measurement of MMPs and needed to have
survived to 6 months post-ART initiation (unless TB-IRIS preceded
their death). For the sub-analysis of lung function,we recruited a conve-
nience sample of patients who had completed participation in the
parent cohort study, had completed their TB treatment with no relapse
or recurrence of TB, were onART, and did not have symptomatic pulmo-
nary infection, or other signs of active pulmonary pathology at the time
of the pulmonary function test (PFT).
2.4. Data Collection
We accessed clinical variables and measures of early immunologic
response on ART from the parent study database (Ravimohan et al.
2015a; Ravimohan et al. 2015b). Baseline blood for MMP and
immune responses assessments was collected at a median of−2 days
(interquartile range [IQR]:−14 to 0 days) from day of ART initiation.
The second blood draw was at median of 2 days (IQR: 0 to 5 days)
from date of the week-4 post-ART initiation. In the parent study,
patients who experienced TB-IRIS in the ﬁrst 6 months of ART were de-
ﬁned as per the International Network for Study of HIV-associated IRIS
and the AIDS Clinical Trials Group criteria, as described previously
(Meintjes et al. 2008; Ravimohan et al. 2015a; Grant et al. 2010). In
addition, we prospectively collected data on smoking as well as height,
weight, and body mass index (BMI) at the time of PFTs to facilitate
calculation of predictive lung function, as per American Thoracic Society
(ATS) guidelines (American Thoracic Society 1995).
2.5. Luminex Assay
Previously frozen (−80 °C) plasma received two dilutions, 1:5 and
1:50, to be within the linear range. We typically used the 1:5 dilution
to determine MMP-1 (lower limit of detection [LLD]: 1.1 pg/ml) and
MMP-3 (LLD: 7.3 pg/ml) and the 1:50 fold dilution to quantitate
MMP-2 (LLD: 12.6 pg/ml), MMP-8 (LLD: 16.6 pg/ml), and MMP-9
(LLD: 13.7 pg/ml) concentration (R&D, Minnesota USA). Four of the
total 296 (1.3%) samples tested had MMP-8 levels that were below
the limit of detection and were recorded as 16.6 pg/ml for analysis.
The luminex assaywas carried out according tomanufacturer's protocol
and analyzed on the Biorad Bio-Plex2000 platform.
2.6. TB-speciﬁc Cellular Immune Responses
Brieﬂy, peripheral blood mononuclear cells (PBMCs) were isolated
from whole blood at baseline and week 4 post-ART initiation, as previ-
ously described (Ravimohan et al. 2013; Ravimohan et al. 2015a). In
IFN-γ enzyme-linked immunosorbent spot (ELISPOT) assays, 2 × 105
cells were incubated overnight with and without puriﬁed protein
derivative (PPD; 5 μg/ml; Statens Serum Institute), in triplicate, and de-
veloped as per manufacturer's protocol (BD Bioscience) (Ravimohan
et al. 2013; Ravimohan et al. 2015a). Plates were read using an
ImmunoSpot reader (Cellular Technology Limited). The average num-
ber of spot forming units (SFU) following subtraction of the negative
control from the PPD stimulated wells was determined and expressed
as SFU/106 PBMCs. Phorbol 12-myristate 13-acetate (50 ng/ml) and
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For ﬂow cytometry, also described previously (Ravimohan et al.
2015b), cryopreserved PBMCs were thawed in a complete RPMI 1640
medium (Gibco) containing 10% fetal bovine serum (Gemini Bio-
Products) and DNase (50 μg/ml, Sigma Aldrich). Cells were stimulated
for 6 h with and without PPD (5 μg/ml) and co-stimulated with CD28/
CD49d (BD FastImmune). Cells were stained with LIVE/DEAD ﬁxable
aqua, anti-CD3-BV570, and anti-CD4-Qdot-705 for identiﬁcation of
live, CD4+ T-cells. Intracellular cytokine staining with anti-IFN-γ-
Paciﬁc blue and anti-TNF-α-AF700 was performed. Antibodies were
obtained from Biolegend, eBiosciences, and Life Technologies. Stained
PBMCs were analyzed on an LSR II (BD Biosciences) and using FlowJo
Version 9.8.2 (TreeStar). To determine TB-speciﬁc responses, frequency
of cells expressing IFN-γ or TNF-α in the negative control was deducted
from the corresponding PPD-stimulated response.
2.7. Pulmonary Function Tests
PFTs were conducted by spirometry in accordance with ATS guide-
lines using the SpiroOne USB device (Micro Medical, U.K.) (American
Thoracic Society 1995). Aminimumof three and up to 8 testmaneuvers
per patient were carried out. The best of threemaximal efforts with less
than 5% variation betweenmaneuvers was deemed “valid” and used for
analysis (American Thoracic Society 1995). The ﬂow-volume loop gen-
erated from the spirometry test was used to determine forced expirato-
ry volume in one second (FEV1), forced vital capacity (FVC), and FEV1/
FVC ratio. As per ATS guidelines, lung function was classiﬁed as normal
or abnormal, where normal lung function was deﬁned as forced expira-
tory volume in one second (FEV1) ≥80%, forced vital capacity (FVC)
≥80%, and FEV1/FVC ratio ≥70% of predicted values (American
Thoracic Society 1991; Pellegrino et al. 2005). Impaired lung function
was deﬁned as FVC or FEV1 b80% of the predicted value and further cat-
egorized as obstructive (FEV1/FVC b 70% and FVC N 80% of predicted
values), restrictive (FEV1/FVC ≥ 70% and FVC b 80% of predicted values),
or mixed defects (FEV1/FVC b 70% and FVC b 80% of predicted values)
(American Thoracic Society 1991; Pellegrino et al. 2005). The
European Community of Coal and Steel (ECCS) reference values were
used to determine percent predicted FEV1 and FVC (Quanjer et al.
1993), which have been suggested for general use in similar African
populations (White et al. 1996).
2.8. Statistical Analysis
Continuous variables were described using medians and IQR or
means and ranges based on the distribution of the variable. To describe
changes in MMPs early during ART, paired measures of MMPs at base-
line andweek 4 post-ART initiation were comparedwithin each subject
byWilcoxon signed rank tests. For the primary analysis of TB-IRIS,MMP
concentrations (exposure) were ﬁrst compared between patients with
TB-IRIS (outcome) and non-IRIS survivors by Wilcoxon rank sum tests.
Testswere two-sided andp values of b0.05were considered statistically
signiﬁcant. Logistic regression was used to determine the association
between early change in MMP concentrations from baseline to week 4
(stratiﬁed into quartiles) and TB-IRIS, adjusting for BMI and use of nevi-
rapine (NVP), both of which were associated with the outcome in this
cohort (Ravimohan et al. 2015a). In the exploratory analyses of lung
function, patients with PFTswere compared to thosewithout lung func-
tion assessments from the primary analysis by the Wilcoxon rank sum
test. Spearman's correlation coefﬁcient (r) was used to determine the
relationship between PFT measures (FEV1 and FVC) assessed after TB
treatment completion and early change from baseline to week 4 of
ART in 1) immunologic response (CD4 count as well as TB-speciﬁc im-
mune response by ELISPOT assay and ﬂow cytometry) and 2)MMP con-
centrations following ART initiation. The association between ATS-
deﬁned abnormal lung function post-TB treatment and change in
MMPs were determined by Wilcoxon rank sum tests. Baseline factors(e.g. pre-ART CD4 count andMMP concentration) that could potentially
confound this association were similarly evaluated. Lung function in
those with a history of TB-IRIS was also compared to those without a
history of IRIS using a chi-square test. Given the small numbers, com-
parisons involving lung function are unadjusted for potential con-
founders. In univariable analyses of the association between change in
MMPs and IRIS as well as in the comparisons between change in im-
mune function, MMPs, and PFT, uncorrected p values and p values
corrected for multiple comparisons using the Benjamini–Hochberg
method are presented (Benjamini and Hochberg 1995). Stata software
(Version 11.2; College Station, Texas) and GraphPad Prism (Version
5.0; San Diego, California) were used for statistical analyses and to gen-
erate graphs, respectively.
2.9. Funding
This study was funded by grants from the National Institutes of
Health (NIH) (grant number R01AI080337) and the Penn Center for
AIDS Research (AI045008). The sponsors did not play a role in data
collection, analysis, or interpretation; design of the study; or patient
recruitment. We have not been paid to write this article by any agency
or pharmaceutical company.
3. Results
3.1. Baseline Characteristics
One hundred and seventy patients were enrolled and initiated on
ART in the parent study (Ravimohan et al. 2015a). Of these patients,
148 (74%) had paired MMP data at pre- and week 4 post-ART initiation
and qualiﬁed for the current study. Patients who were excluded were
not signiﬁcantly different from those who were included in terms of
age, sex, and CD4 count at baseline (data not shown). Thirty-two pa-
tients (22%) developed TB-IRIS, leaving 116 (78%) non-IRIS survivors.
Clinical symptoms associatedwith TB-IRISwere primarily new orwors-
ening respiratory complaints occurring at amedian of 4weeks post-ART
initiation (IQR: 4–12 weeks) and have been previously described
(Ravimohan et al. 2015a). One (3%) of the TB-IRIS patients died two
weeks after the IRIS event despite initial improvement on corticosteroid
therapy and was included in the primary analysis as a TB-IRIS case
(Ravimohan et al. 2015a). Overall, patients had median pre-ART CD4
counts of 62 cells/μl (IQR: 32–94 cells/μl) and started ART within
28 days (IQR: 19–47 days) of TB treatment initiation (Supplemental
Table 1).
3.2. Changes in MMP Concentrations After ART Initiation
Therewas considerable heterogeneitywith respect to changes in the
concentration of MMPs, measured from baseline to week 4 post-ART
initiation (Fig. 1 and Supplemental Fig. 1). Median concentrations of
MMP-1, -2, and -3 decreased, whereas MMP-8 and 9 concentrations
increased signiﬁcantly (all p b 0.01 except MMP-1, which was non-
signiﬁcant; Fig. 1).
3.3. TB-IRIS and MMP Concentrations Following ART Initiation
Patients who experienced TB-IRIS had signiﬁcantly greater increases
in MMP-8 concentrations on ART compared to non-IRIS controls in
unadjusted analyses (p = 0.04; pcorr = 0.13; Table 1). Every quartile
increase in MMP-8 from baseline to week 4 post-ART initiation was
independently associated with a 50% higher odds of TB-IRIS, after
adjusting for baseline CD4 count, BMI, and NVP use (odds ratio 1.5
[95% conﬁdence interval: 1.0–2.1]). Changes in all other MMPs were
not statistically different between groups (Table 1).
Fig. 1.MMPconcentrations change soon afterART initiation in advancedHIV/TB co-infected
patients. Luminex assay was used to quantitate plasma concentrations of matrix metallo-
proteinase (MMP)-1, -2, -3, -8, and -9 pre- (gray) and week 4 post-ART initiation (black)
in advanced HIV/TB co-infected patients (n = 148). Median MMP concentrations with
interquartile ranges are shown in red. Wilcoxon sign rank test was used to compare
matched pair baseline and week 4 post-ART concentration of MMPs within all patients.
N.s. = non-signiﬁcant, *p b 0.01, **p b 0.001, ***p b 0.0001.
Table 2
Clinical characteristics and pulmonary function post-TB treatment completion in ad-
vanced HIV/TB co-infected patients.
Clinical variables (n = 14)
Female, n (%) 7 (50%)
Pre-ART HIV viral load, log10 copies/ml (IQR) 5.2 (4.7–6.0)
Pre-ART CD4 T-cell count, median cells/μl (IQR) 36 (24–79)
Age at PFT, mean (range in years) 40 (27–61)
BMI at PFT, median kg/m2 (IQR); 21.5 (19.4–23)
History of smoking, n (%) 2 (14)
ATT initiation-PFT median years (IQR) 1.9 (1.6–2.1)
ART initiation-PFT median years (IQR) 1.8 (1.5–2.1)
Pulmonary function test (PFT)
FEV1a, median % (IQR) 77.5 (66–83)
FVCa, median % (IQR) 83 (77–91)
FEV1/FVC ratioa, median % (IQR) 97.5 (76–105)
Abnormal PFT, n (%) 9 (64)
Obstructive, n (%) 5 (56)
Restrictive, n (%) 3 (33)
Mixed, n (%) 1 (11)
Shown are characteristics at baseline and at cross-section for patientswhounderwent pul-
monary function testing (PFT) post-TB treatment completion. IQR = interquartile range;
BMI = body mass index; ATT = anti-TB therapy; FEV1 = forced expiratory volume in 1
s; FVC = forced vital capacity.
a Percent of predicted normal.
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PFTs were conducted in a convenience sample of 14 patients
nearly 2 years following a standard 6-month course of anti-TB therapy
(Table 2), when TB-associated acute effects on lung function have
been shown to have stabilized (Hnizdo et al. 2000). The subset of pa-
tients with PFTs was relatively representative of the overall cohort, as
there were no major differences between those with (n = 14) and
without (n = 134) PFT assessments (Supplemental Table 2). Further-
more, while changes in MMP-1 and MMP-3 concentrations as well as
TB-speciﬁc IFN-γ+ and TNF-α+ CD4+ T-cell frequencies were some-
what different for this sub-group compared to the overall cohort, they
were not statistically signiﬁcant (Supplemental Table 2). Half of the pa-
tients with PFT analysis were female (n = 7) and two (14%) had a his-
tory of smoking. The median percent predicted FEV1 for these patients
was below the cut-off for normal lung function (78% [IQR: 66–83%]).
Nine (64%) patients had ATS-deﬁned abnormal lung function, of
which 5 (56%) were categorized as obstructive, 3 (33%) as restrictive,
and 1 (11%) as mixed pulmonary defects (Table 2).
Increases in MMP-8, but not other MMPs, early after ART
initiation were strongly associated with lower FEV1 after TB treatment
completion (p = 0.02; pcorr = 0.09; Table 3 and Fig. 2a). Assessing the
association between abnormal lung function and change in MMPs
revealed that increase in MMP-8 on ART was linked to abnormalTable 1
Change from baseline to week 4 post-ART initiation in MMPs and association with TB-IRIS amo
Change from baseline median (IQR) Overall
(n = 148)
Control
(n = 116)
MMP-1 −92.2 (−3685 to 4326) −127 (−
MMP-2b −28.0 (−122.1 to 45.4) −10 (−
MMP-3 −1,876 (−5196 to 1289) −2391 (−
MMP-8 580 (−1302 to 5110) 421 (−
MMP-9 9015 (504 to 26,570) 9858 (80
Wilcoxon rank sum test was used to compare controls to TB-IRIS patients. P b 0.05 was consid
a Pcorr = p value adjusted for multiple comparisons using the Benjamini–Hochberg method
b Luminex data for matrix metalloproteinase (MMP)-2 is shown as ng/ml, while all other Mpulmonary function, while those with normal lung function generally
had an early reduction in MMP-8 (p = 0.04; Fig. 2b and Supplemental
Table 3). Furthermore, a strong inverse correlation was observed
between the magnitude of the rise of CD4 count from baseline to
week 4 of ART and the percent predicted FEV1 after TB treatment com-
pletion (p= 0.006; pcorr = 0.05; Table 3 and Fig. 3a). Greater increases
in IFN-γ released by total PBMC as well as IFN-γ+ or TNF-α+ CD4+
T-cell frequency also tended to correlate with a lower percent predicted
FEV1 after TB treatment completion; however, these relationships were
not statistically signiﬁcant (Table 3; Fig. 3b and c).
Furthermore, 3 (21%) of 14 patients with PFT analyses had a history
of paradoxical TB-IRIS. IRIS onset among these three patientswas at 4, 4,
and 16 weeks post-ART initiation, and symptoms persisted between 4
and 8weeks. These patients presentedwith signs and symptoms consis-
tent with TB-IRIS, such as new onset cervical lymphadenopathy, as well
as respiratory complaints, which included dyspnea and chest pains. CD4
count increase on ART among the three TB-IRIS cases was 69, 126 and
181 cells/μl and HIV viral load was decreased by median −3.0, −2.7
and −2.2 log10 copies/ml. TB-IRIS patients had signiﬁcantly worse
FEV1 values than those without IRIS (median percent predicted
FEV1 = 65%, [IQR: 46–72] versus 79% [IQR: 76–86]; p = 0.04,
respectively). Additionally, TB-IRIS patients had signiﬁcantly lower
FEV1/FVC ratio compared to non-IRIS controls (median percent predict-
ed FEV1/FVC = 75 [IQR: 60–76] versus 100 [IQR: 81–110], respectively,
p = 0.02).
Since we did not have baseline lung function data on participants
and associations between changes in MMP concentrations and CD4ng advanced HIV/TB co-infected patients.
TB-IRIS
(n = 32)
P value Pcorr valuea
4186 to 4569) −8.9 (−2726 to 2690) 0.57 0.59
112.8 to 62.6) −52.3 (−166.2 to 6.2) 0.07 0.13
6124 to 653) −1018 (−3103 to 2701) 0.08 0.13
2070 to 4538) 3195 (69 to 10,070) 0.04 0.13
8 to 26,506) 5395 (−134 to 29,239) 0.59 0.59
ered statistically signiﬁcant. IQR = interquartile range.
.
MPs are presented as pg/ml.
Table 3
Association between lung function post-TB treatment completion and change from base-
line to week 4 post-ART initiation in immune parameters and MMPs in HIV-infected pa-
tients with a history of treated pTB.
Variable Rho# P value Pcorr value§
FEV1 association with change from baseline to week 4 post-ART in
CD4 count −0.70 0.006 0.05
TB-speciﬁc IFN-γ ELISPOT* −0.35 0.21 0.42
CD4+IFN-γ+ T-cell** (n = 10) −0.40 0.25 0.42
CD4+TNF-α+ T-cell** (n = 10) −0.54 0.10 0.30
MMP-1 −0.24 0.42 0.54
MMP-2 −0.07 0.81 0.81
MMP-3 0.31 0.28 0.42
MMP-8 −0.60 0.02 0.09
MMP-9 0.16 0.59 0.66
FVC association with change from baseline to week 4 post-ART in
CD4 count −0.26 0.37 0.55
TB-speciﬁc IFN-γ ELISPOT* −0.18 0.53 0.60
CD4+IFN-γ+ T-cell** (n = 10) −0.36 0.31 0.55
CD4+TNF-α+ T-cell** (n = 10) −0.28 0.43 0.55
MMP-1 −0.52 0.06 0.54
MMP-2 −0.03 0.90 0.90
MMP-3 −0.33 0.24 0.55
MMP-8 −0.28 0.33 0.55
MMP-9 −0.29 0.31 0.55
Shown are Spearman's correlation coefﬁcients (rho)#. §Pcorr = p value adjusted for multi-
ple comparisons using the Benjamini–Hochberg method. *IFN-γ produced by peripheral
bloodmononuclear cells (PBMC)wasmeasured by ELISPOT assay. PBMCswere stimulated
with puriﬁed protein derivative (PPD) to measure TB-speciﬁc immune responses
expressed as spot forming units (SFU)/106 PBMCs. **Frequency of CD4+ T-cell expressing
IFN-γ or TNF-α in response to PPD stimulation was assessed by intracellular cytokine
staining and ﬂow cytometry.
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rameters at initial presentation, we compared baseline levels of CD4
counts and MMP concentrations among those with and without abnor-
mal lung function (Supplemental Table 3). Patients with ATS-deﬁned
abnormal lung function tended to have lower median pre-ART
CD4 counts; slightly longer interval between anti-TB therapy and ART
initiation; and lower pre-ART MMP-8 concentrations compared to
patients with normal lung function; however, these associations did
not reach statistical signiﬁcance (Supplemental Table 3).
4. Discussion
In this studywe investigated circulating concentrations of keyMMPs
before and soon after ART initiation among a relatively large cohort ofFig. 2. Increases inMMP-8 concentrations from baseline to week 4 post-ART initiation is associa
function post-TB treatment inHIV-infected patients with a history of active pTB. FEV1wasmeas
(n = 14) to determine percent predicted of normal. Normal and abnormal lung function we
luminex assay. Shown is the Spearman correlation coefﬁcient (r) and corresponding p value (a
those with abnormal lung function (b).advanced HIV-infected patients concurrently treated for active pTB.
While there was substantial heterogeneity in early MMP changes,
concentrations of MMP-8 and -9 increased signiﬁcantly on ART and
greater early MMP-8 increases were associated with both TB-IRIS and
decreased lung function months after TB cure, a time when TB-
associated lung damage has typically stabilized (Hnizdo et al. 2000).
Similarly, rapid increases in the CD4 count early after ART were also as-
sociatedwithworse lung function after TB treatment completion. These
ﬁndings, combined with data that MMPs and cellular immune re-
sponses are key to granuloma and cavity formation in TB (Salgame
2011; Dutta and Karakousis 2014), support a hypothesis where early
changes in immune function and relevant tissue proteases following
ART initiation contribute to long-term pulmonary function deﬁcits
post-TB cure in HIV/TB. Our data also indicate that patients with
clinically apparent inﬂammatory events, such as those with TB-IRIS,
may be especially at risk.
Previous work has indicated that MMPs degrade lung collagen ma-
trix and mediate lung tissue destruction in TB (Ong et al. 2014;
Elkington et al. 2011; Elkington and Friedland 2006; Ong et al. 2015).
Thus, our ﬁnding that systemic concentrations of MMP-8 and MMP-9
increase rapidly following ART initiation, as well as the association be-
tween increases in MMP-8 and TB-IRIS, which is frequently character-
ized by respiratory complaints (Meintjes et al. 2008; Naidoo et al.
2012; Luetkemeyer et al. 2014), suggest that HIV-infected patients
with active pulmonary TB may be at risk for incident immune-
mediated lung damage after ART initiation. While a somewhat consis-
tent relationship emerged with MMP-8 and outcomes in this study, it
is notable that concentrations of MMP-1, -2, and -3, which have also
been implicated in lung tissue destruction (Ong et al. 2014; Elkington
et al. 2011; Elkington and Friedland 2006), decreased or remained
unchanged on ART. One possibility is that MMP-1 and -2 have highly
compartmentalized expression at the site of infection, as demonstrated
in a study of pleural tuberculosis (Hoheisel et al. 2001). Furthermore,
another study showed that rifampicin can downregulate MMP-3
expression in vitro, whichmay explain decreases in circulating concen-
trations of MMP-3 in our patients, all of whomwere on this drug (Singh
et al. 2014). Our results are broadly consistent with a cross-sectional
study of MMPs in paradoxical TB-IRIS by Tadokera et al., where concen-
tration of MMP-7 in MTB-stimulated PBMC culture supernatants and
serum were signiﬁcantly higher in those with TB-IRIS (n = 22) com-
pared to non-IRIS controls (n = 22) (Tadokera et al. 2014). The
Tadokera study did not ﬁnd an association between MMP-8 and
IRIS when assessing MTB-stimulated PBMCs (Tadokera et al. 2014);
however, this may relate to the fact that MMP-8 is predominantlyted with (a) lower forced expiratory volume in one-second (FEV1) and (b) abnormal lung
ured by pulmonary function testing post-TB treatment completion inHIV-infected patients
re deﬁned as per American Thoracic Society (ATS) guidelines. MMP-8 was measured by
) as well as the p value fromWilcoxon rank sum test comparing patients with normal to
Fig. 3. Lower FEV1 post-TB treatment completion is correlated with greater increases in immune function from baseline to week 4 post-ART initiation in HIV-infected patients with a
history of active pTB. Forced expiratory volume in one-second (FEV1) was measured by pulmonary function testing post-TB treatment completion in HIV-infected patients to determine
percent predicted of normal. Shownare Spearman's correlation coefﬁcients (rho: r) and corresponding p values comparing percent predicted FEV1 to change frombaseline toweek 4 post-
ART in (a) CD4 count (n = 14) and (b) frequency of IFN-γ and (c) TNF-α producing CD4+ T-cells (n = 10) upon PPD stimulation.
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lost during the PBMC isolation process. MMP concentrations are highly
dynamic during TB treatment (Ugarte-Gil et al. 2013), and therefore dif-
ferences between the two studies may also relate to the fact that pa-
tients in the Tadokera study had a substantially longer time to ART
initiation after startingTB treatment than those includedhere (56versus
28 days), whereas time to TB-IRIS was markedly shorter (14 versus
28 days) (Tadokera et al. 2014). Our relatively large population of nearly
150 patients with advanced HIV/TB and the consistent association be-
tween changes in MMP-8 concentrations and both TB-IRIS and lung
function suggest a compelling role forMMP-8 recovery in inﬂammatory
events and tissue damage on ART that should be investigated in further
detail. Taken together, the two studies indicate that additional research
on the pathogenesis of tissue damage in patients with HIV/TB initiating
ART is needed.
An association between reconstitution of CD4 T-cells and impaired
lung function,measured as oxygen saturation, has been shown in amu-
rine model for IRIS using Mycobacterium avium (Barber et al. 2010).
However, our study investigated the association between paradoxical
TB-IRIS, change in MMPs on ART, and pulmonary function post-TB
cure amongHIV/TB co-infected patients. Our evaluation of lung function
demonstrated not only lower FEV1 in TB-IRIS patients compared to non-
IRIS controls, but also that the magnitude of the early CD4 cell increase
and circulating MMP-8 concentrations following ART initiation were
associated with impaired FEV1 post-TB cure. While the number of pa-
tients assessed using PFTs was small and this subset may not be entirely
representative of the larger cohort with respect to certain MMPs
(i.e., MMP-1 and -3) and TB-speciﬁc immune responses, the strength
of the associations (r =−0.7 and r =−0.6) suggests that further re-
search on this association is needed. Impairment of FEV1, which primar-
ily measures airﬂow through large airways, ﬁts with the endobronchial
involvement characteristic of TB and with at least one anecdotal report
of severe bronchiolitis obliterans after ART initiation in HIV/TB (Lawn
et al. 2009). While our ﬁndings were among advanced HIV/TB patients
initiatingART, they urge future studies to investigate end-organdamage
in TB-IRIS and more generally among HIV/TB co-infected patients initi-
ating ART. Central nervous system (CNS) impairment following
TB-meningitis associated IRIS is also a concern, as signiﬁcant localized
increases in cellular immune function and MMPs have been previously
noted (Marais et al. 2014).
Mechanistically, reduced lung involvement in advanced HIV-
infected patients has been linked to low CD4 counts and reduced con-
centrations of MMPs, both of which are important to granuloma forma-
tion and cavitation (Kwan and Ernst 2011; Post et al. 1995;Walker et al.2012; Zhang et al. 1994; Law et al. 1996). While we did not determine
the source of MMPs, neutrophils may also be involved, as discussed
above. Neutrophils, which are noted to be the predominant phagocytic
cell type in the airway of TB patients (Eum et al. 2010), were found to
express MMP-8 and -9 in the lining of TB cavities (Ong et al. 2015),
supporting a possible role in the pathogenesis of the lung impairment
we observed. It is plausible that reconstituted CD4 T-cell and neutrophil
activity following ART initiation in the setting of incompletely treated
TB contribute, in part, to the rise in MMP-8 concentrations on ART, as
seen here (Appelberg 1992; Zhang et al. 1992). Neutrophil inﬁltration
to the disease site soon after ART initiation has been suggested in a
study of TB meningitis IRIS among HIV-infected patients (Marais et al.
2013). Furthermore, MMP-8 expression differs from other MMPs
in that neutrophils contain granules with pre-synthesized MMP-8
and have the potential to secrete MMP-8 rapidly upon activation
(Elkington and Friedland 2006; Hasty et al. 1986; Weiss et al. 1985).
Thus, the ensuing increase in immune function andMMPs on ART, per-
haps driven by neutrophils, could potentially underlie incident lung tis-
sue damage and worsening the airﬂow obstruction that frequently
accompanies TB (Pasipanodya et al. 2010; Hnizdo et al. 2000; Ralph
et al. 2013). Our data collection did not include neutrophil numbers,
but these ﬁndings need conﬁrmation in larger studies where longitudi-
nal assessments of immune and pulmonary function are assessed in
more detail. Furthermore, future studies should aim to identify the pri-
mary site of lung injury and the predominant form of ventilator defects
in HIV/TB co-infected patients following pTB treatment completion.
Our study was limited by the relatively small number of patients
with PFTs, which restricted our assessment of potential confounding.
Another important limitation of our study is that we did not have base-
line lung function assessments to determine if patients with pulmonary
impairment post-TB treatment completion, as measured here, also
started off with worse lung function before ART initiation. However,
patients in the studywho had abnormal lung function post-cure tended
to have lower pre-ART CD4 counts and MMP-8 concentration, both of
which are associated with less lung involvement in HIV/TB (Kwan and
Ernst 2011; Walker et al. 2012; Law et al. 1996). Additionally, chest ra-
diographs, which we did not have at baseline or during follow-up,
would have further enabled evaluation of lung involvement during
treatment. Another limitation of our study was that we excluded pa-
tients who did not survive to 6 months post-ART initiation from our
analyses. These patients may have had poor lung function. However,
as the aim of our study was to investigate the determinants of lung im-
pairment after TB treatment completion, we excluded deaths as they
did not survive to this time point.
106 S. Ravimohan et al. / EBioMedicine 3 (2016) 100–107In summary, rapid changes in the concentrations of multiple MMPs
were observed on ART, where rise inMMP-8was independently associ-
ated with TB-IRIS. Increase in cellular immune function andMMP-8 fol-
lowing ART initiation was also linked with depressed lung function
several months post-TB cure. MMPs like MMP-8 may be potential
targets for host-directed therapy if found to mediate lung injury in
future studies that aim to determine the mechanisms of lung damage
in HIV/TB. In particular, the association between reversion of patients
to a more immunocompetent phenotype, afforded by potent ART,
with lung damage should be explored further.
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